Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technetium-99m Radiolabeled Carboplatin Polymeric Nanoparticles for Imaging and Treatment of Epithelial Ovarian Cancer.

Current medicinal chemistry·2026
Same author

Lipoxin A4 (LXA<sub>4</sub>) versus Nanolipoxin A4 (Nano-LXA<sub>4</sub>) for osteosarcoma.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

IGF2R-Targeted Alpha Therapy of Osteosarcoma Enabled by Conjugated [<sup>225</sup>Ac]Ac-Macropa-PEG<sub>4</sub>-IF3.

Bioconjugate chemistry·2026
Same author

Nanoceria as an Innovative Therapy for Endometriosis: Impact on Lesion Reduction and Therapeutic Optimization.

Current medicinal chemistry·2026
Same author

Evaluation of Antitumor and Antimicrobial Photobiological Activity of Nanocarrier Containing Photosensitizer and Magnetic Nanoparticle.

Current issues in molecular biology·2026
Same author

Optimized Milling Approaches for Scalable Production of Ritonavir Nanocrystals: from Process Design to Bioperformance Evaluation.

ACS omega·2026

Related Experiment Video

Updated: Jun 27, 2026

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
10:16

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets

Published on: March 12, 2019

Radiopharmaceutical drug interactions.

Ralph Santos-Oliveira1

  • 1Radiopharmaceutical Quality Control Service, Brazilian Nuclear Energy Commission, Recife, Brazil. roliveira@cnen.gov.br

Revista De Salud Publica (Bogota, Colombia)
|December 2, 2008
PubMed
Summary

Under-reporting of drug and radiopharmaceutical interactions is a significant issue in nuclear medicine. Improving reporting of adverse events is crucial for patient safety and diagnostic accuracy.

Area of Science:

  • Nuclear Medicine
  • Radiopharmacology
  • Patient Safety

Background:

  • Significant under-reporting of drug and radiopharmaceutical interactions, security issues, and adverse reactions exists.
  • Increasing utilization of radiopharmaceuticals necessitates greater attention from nuclear medicine professionals and regulatory agencies.
  • Current reporting mechanisms may not fully capture the scope of adverse events or near misses.

Purpose of the Study:

  • To establish a comprehensive reference for adverse reactions associated with radiopharmaceuticals.
  • To support nuclear medicine staff in their daily practice by providing accessible information.
  • To encourage improved reporting of adverse events and near misses to enhance patient care.

Main Methods:

  • Literature review of reported adverse events and drug interactions.

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Jun 27, 2026

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
10:16

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets

Published on: March 12, 2019

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

  • Analysis of current reporting practices in nuclear medicine.
  • Development of a structured reference guide for adverse reactions.

    • Main Results:

    • Identified a substantial gap in the reporting of radiopharmaceutical-related adverse events.
    • Highlighted the need for standardized reporting protocols.
    • Emphasized the importance of near-miss reporting in risk assessment.

    Conclusions:

    • Enhanced reporting of adverse events and drug interactions is vital for nuclear medicine.
    • A readily available reference for adverse reactions can improve staff awareness and management.
    • Proactive reporting contributes to improved diagnostic accuracy and patient safety.